专业监测看板

CTIS 登记变化 · 欧盟 CTIS

INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)

登记状态：总体：已批准，招募中；国家：比利时：进行中，已结束招募 → 已结束

企业 / 申办者：Incyte Corp.

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A Two Part Phase IIa/b Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Dose ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension

登记状态：总体：进行中，已结束招募 → 已结束；国家：西班牙：进行中，已结束招募 → 已结束

企业 / 申办者：Astrazeneca AB

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65).

登记状态：总体：进行中，已结束招募；国家：德国：进行中，已结束招募 → 已结束

企业 / 申办者：Merck Sharp & Dohme LLC

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

登记状态：总体：进行中，已结束招募；国家：克罗地亚：进行中，已结束招募 → 已结束

企业 / 申办者：Celltrion Inc.

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients with Spinal Muscular Atrophy After Gene Therapy

登记状态：总体：进行中，已结束招募；国家：德国：进行中，招募中 → 进行中，已结束招募

企业 / 申办者：F. Hoffmann-La Roche AG

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection

登记状态：总体：进行中，已结束招募；国家：波兰：暂时中止 → 进行中，已结束招募

企业 / 申办者：Merck Sharp & Dohme LLC

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

登记状态：总体：进行中，已结束招募；国家：波兰：进行中，已结束招募 → 已结束

企业 / 申办者：F. Hoffmann-La Roche AG

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis

登记状态：总体：进行中，已结束招募；国家：德国：进行中，已结束招募 → 已结束

企业 / 申办者：Dr. Falk Pharma GmbH

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progression in Huntington's disease patients.

登记状态：总体：进行中，已结束招募 → 进行中，招募中；国家：西班牙：进行中，已结束招募 → 进行中，招募中

企业 / 申办者：IIS La Fe

发现时间：2026/11/11 14:34:11

CTIS 登记变化 · 欧盟 CTIS

A First-In-Human (FIH) phase I/II open-label, multicenter, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations

登记状态：总体：进行中，已结束招募；国家：荷兰：进行中，已结束招募 → 已结束

企业 / 申办者：Pierre Fabre Medicament

发现时间：2026/11/11 14:34:11